Amiodarone-induced pneumonitis.

Published on Feb 27, 2021in QJM: An International Journal of Medicine2.529
· DOI :10.1093/QJMED/HCAB045
Hiroki Matsuura4
Estimated H-index: 4
,
Yoshihiko Kiura1
Estimated H-index: 1
+ 4 AuthorsMasayuki Kishida11
Estimated H-index: 11
Source
Abstract
References2
Newest
#1Nora Goldschlager (UCSF: University of California, San Francisco)H-Index: 32
#2Andrew E. Epstein (UA: University of Alabama)H-Index: 64
Last. Elizabeth Murphy (UCSF: University of California, San Francisco)H-Index: 106
view all 7 authors...
Amiodarone is commonly used to treat supraventricular and ventricular arrhythmias in various inpatient and outpatient settings. Over- and under-use of amiodarone is common, and data regarding patterns of use are sparse and largely anecdotal. Because of adverse drug reactions, proper use is essential to deriving optimal benefits from the drug with the least risk. This guide updates an earlier version
164 CitationsSource
#1Philippe Camus (University of Burgundy)H-Index: 26
#2William J. Martin (UC: University of Cincinnati)H-Index: 2
Last. Edward C. Rosenow (UR: University of Rochester)H-Index: 11
view all 3 authors...
The amount of literature on amiodarone pulmonary toxicity (APT) peaked in 1983-1984 with several hundred cases reported cumulatively, and declined thereafter. Since the mid-1990s, publications have increased, which suggests that APT remains a current problem in clinical practice. Amiodarone remains difficult to diagnose noninvasively, and although the outcome is good in the majority of patients, not all cases of APT can be controlled satisfactorily.
117 CitationsSource
Cited By0
Newest